National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Semaglutide (Rybelsus®) HTA ID: 20011

Oral semaglutide (Rybelsus®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise:

(a)          as monotherapy when metformin is considered inappropriate due to intolerance or contraindications.

(b)           in combination with other medicinal products for the treatment of diabetes.

 

NCPE Assessment Process Complete
Rapid review commissioned 02/03/2020
Rapid review completed 30/03/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost-effectiveness of oral semaglutide (Rybelsus®) compared with the current standard of care.

 

Full pharmacoeconomic assessment commissioned by HSE 07/04/2020
Pre-submission consultation with Applicant 16/06/2020
Full submission received from Applicant 18/11/2020
Preliminary review sent to Applicant 21/12/2020
NCPE assessment re-commenced 29/01/2021
Factual accuracy sent to Applicant 04/02/2021
NCPE assessment re-commenced 11/02/2021
NCPE assessment completed 17/02/2021
NCPE assessment outcome The NCPE recommends that oral semaglutide should not be considered for reimbursement unless cost-effectiveness can be improved relative to existing therapy*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.